KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $164.1 million.

  • Neogenomics' Cash & Current Investments fell 57.68% to $164.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 31.92%. This contributed to the annual value of $386.8 million for FY2024, which is 6.83% down from last year.
  • Neogenomics' Cash & Current Investments amounted to $164.1 million in Q3 2025, which was up 0.26% from $163.7 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Cash & Current Investments peaked at $802.7 million during Q1 2021, and registered a low of $163.7 million during Q2 2025.
  • Over the past 3 years, Neogenomics' median Cash & Current Investments value was $387.8 million (recorded in 2024), while the average stood at $352.5 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 830.60% in 2021, then plummeted by 57.80% in 2025.
  • Neogenomics' Cash & Current Investments (Quarterly) stood at $515.4 million in 2021, then decreased by 15.02% to $438.0 million in 2022, then declined by 5.20% to $415.2 million in 2023, then dropped by 6.83% to $386.8 million in 2024, then crashed by 57.68% to $164.1 million in 2025.
  • Its last three reported values are $164.1 million in Q3 2025, $163.7 million for Q2 2025, and $358.1 million during Q1 2025.